These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 19745766

  • 1. Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival.
    Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH.
    J Thorac Oncol; 2009 Nov; 4(11):1307-12. PubMed ID: 19745766
    [Abstract] [Full Text] [Related]

  • 2. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH.
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [Abstract] [Full Text] [Related]

  • 3. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH.
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [Abstract] [Full Text] [Related]

  • 4. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 6. The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe.
    Sakao Y, Okumura S, Mingyon M, Uehara H, Ishikawa Y, Nakagawa K.
    J Thorac Oncol; 2011 Mar; 6(3):494-9. PubMed ID: 21266920
    [Abstract] [Full Text] [Related]

  • 7. Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.
    Zhang W, Guo N, Yu C, Wang H, Zhang Y, Xia H, Yu J, Lu J.
    Tumour Biol; 2012 Dec; 33(6):2209-16. PubMed ID: 22890830
    [Abstract] [Full Text] [Related]

  • 8. A pragmatic approach to the diagnosis of nodal micrometastases in early stage non-small cell lung cancer.
    Herpel E, Muley T, Schneider T, Palm E, Kieslich de Hol D, Warth A, Meister M, Storz K, Schnabel PA, Schirmacher P, Dienemann H, Hoffmann H.
    J Thorac Oncol; 2010 Aug; 5(8):1206-12. PubMed ID: 20581709
    [Abstract] [Full Text] [Related]

  • 9. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ.
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [Abstract] [Full Text] [Related]

  • 10. Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.
    Okada M, Sakamoto T, Yuki T, Mimura T, Nitanda H, Miyoshi K, Tsubota N.
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):825-30. PubMed ID: 15821650
    [Abstract] [Full Text] [Related]

  • 11. Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer.
    Prenzel KL, Mönig SP, Sinning JM, Baldus SE, Gutschow CA, Grass G, Schneider PM, Hölscher AH.
    J Surg Oncol; 2003 Apr; 82(4):256-60. PubMed ID: 12672010
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [Abstract] [Full Text] [Related]

  • 13. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    Cancer; 2008 Sep 15; 113(6):1379-86. PubMed ID: 18623378
    [Abstract] [Full Text] [Related]

  • 14. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D.
    Lung Cancer; 2013 Nov 15; 82(2):324-9. PubMed ID: 23993732
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M.
    Anticancer Res; 2012 Nov 15; 32(11):5003-10. PubMed ID: 23155271
    [Abstract] [Full Text] [Related]

  • 16. [Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
    Guo N, Li S, Zhang W, Yu C, Wang H, Zhang Y, Yu J.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Aug 15; 29(8):870-3. PubMed ID: 23948418
    [Abstract] [Full Text] [Related]

  • 17. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T, Sawabata N, Funaki S, Inoue M, Kadota Y, Shintani Y, Okumura M.
    Interact Cardiovasc Thorac Surg; 2011 May 15; 12(5):733-8. PubMed ID: 21297135
    [Abstract] [Full Text] [Related]

  • 18. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M, Choi YD, Cho HJ, Ban HJ, Oh IJ, Kim KS, Song SY, Na KJ, Ahn SJ, Choi S, Kim YC.
    Respirology; 2012 Jan 15; 17(1):127-33. PubMed ID: 21899657
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, Mastroianni B, Souquet PJ, Girard N, Jeannin G, Romand P, Chatellain P, Vesin A, Brambilla C, Brambilla E.
    Lung Cancer; 2014 Feb 15; 83(2):182-8. PubMed ID: 24388706
    [Abstract] [Full Text] [Related]

  • 20. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S, Takabe K, Suzuki K.
    Pathol Int; 2009 Dec 15; 59(12):863-7. PubMed ID: 20021611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.